A new study shows that the highly-popular vaccine used in the US for a rare form of bacterial pneumonia is one of the priciest vaccines ever tested.
The cost of Peptosacin, which has been widely used in hospitals, is about half the cost of a comparable vaccine, according to the analysis by researchers at Tufts University and Johns Hopkins University.
In contrast, the cost for a similar flu shot, which costs about $75 a dose, is almost $50.
The analysis of data from US health insurance companies covering more than 14 million people was published in the medical journal Vaccine.
The research team, led by Tufts associate professor of medicine Edward G. Miller, looked at data on how much a Peptovax vaccine was cost-effective for different populations.
The study found that the cost per person who received Peptomax, a $75 vaccine, was about the same as the cost in the UK for the same drug, according the study.
However, Peptox is less expensive in the United States than in other countries.
For instance, the vaccine cost about $50 in the USA, compared to $90 in France, $100 in the Netherlands and $130 in Germany, the study found.
But this cost difference could be due to a higher cost of treatment and other costs associated with the Peptol vaccine.
In Europe, Pebacovir is about a third cheaper than Peptapres in the same country, according a new analysis from the European Centre for Disease Prevention and Control (ECDC) and the European Institute for Vaccines and Technologies (EIVT).
The researchers found that if people in the U.S. were to receive a Pebavax, the price difference between the two would disappear.
However this would not happen in France.
The researchers also noted that people in Europe who received a vaccine of the same strength from Merck, which is the same brand as the Pebapres vaccine, were less likely to have serious adverse events than those who received the cheaper vaccine from a smaller, non-Merck company.
In fact, they were twice as likely to report serious adverse reactions compared with people who received other generic drugs.
Dr. Miller said it was important to note that the data he and his colleagues were looking at was for the UK population, which includes the U, U.K. and Ireland.
He said it could be a “long-term trend” that people who are already sick and don’t have insurance would have more of an adverse reaction to the cheaper Peptopres vaccine.
“It’s a reminder that people have to take this vaccine seriously, because they’re more likely to get sick,” he said.
The new study comes as the US is struggling to come up with a vaccine for the seasonal flu pandemic, which some believe could take years to get under way.
The vaccine is currently being developed by GlaxoSmithKline and has been the subject of two patents.
It is still not widely used, and the US government has been slow to approve it.
The US has already had several flu pandemics.
More than 7,000 people died of the flu in 2016, according at least one official.
There are more than 1.5 million influenza cases and 2.5m deaths globally.
In the US, there have been about 11,000 deaths from influenza over the past six years.
About half of those cases are in children under five, according Dr. Adam Pashler, the director of the influenza center at the University of Michigan School of Public Health.
Dr Pasher said it is important for the US to get the vaccine right.
“We need to get it out there as soon as we can,” he told ABC News.
“There is no doubt the vaccine will have an impact on the US.
If we have a flu vaccine that works, we’ll be in much better shape.”
The new research suggests the cost could be even higher than that.
For example, in the European Union, the US has been trying to get more people vaccinated, and so has been spending on Pebabacovib, a more expensive version of the vaccine.
But Dr. Pashner said the current cost of this vaccine is likely to be “unacceptably high”.
He said Peptobacoviv was also being developed, and this is another reason why it should be prioritized over Pebampavib.
“That is the biggest reason for all of us to get vaccinated,” he added.
“Because we’re saving lives.”